Hyperfine, Inc. Class A HYPR
NASDAQ · United States · Health Technology
$0.8938+0.02 (+2.54%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
GUILFORD, Conn., September 28, 2026--Hyperfine appoints Roots Pharmaceutical as exclusive Swoop system distributor in the United Arab Emirates and Kuwait.
MENLO PARK, Calif., September 16, 2026--MedtechWOMEN today announced that Maria Sainz, President and CEO of Hyperfine, Inc., has been named the recipient of its 2026 Ferolyn Powell Leadership Award, and that Beverly Tang, co-founder and CEO of Starlight Cardiovascular, has received MedtechWOMEN’s first-ever Rising Star Award. Both leaders were recognized at the annual MedtechVISION Annual Conference at the Rosewood Sand Hill in Menlo Park, Calif.
GUILFORD, Conn., September 15, 2026--Completion of enrollment in study to support anticipated indication expansion for use of the Swoop® system with contrast agents.
GUILFORD, Conn., August 31, 2026--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced plans to participate in the upcoming Lake Street Capital Markets 10th Annual Best Ideas Growth Conference on Thursday, September 10th.
GUILFORD, Conn., August 26, 2026--Peer-reviewed NEURO PMR results and 3,000+ office brain MRI scans support growing use of the Swoop system across neurology practices.
GUILFORD, Conn., August 20, 2026--FDA-cleared Optive AI software enhances Swoop system image quality, clinical utility, ease of use, and isotropic imaging capability.
Moby summary of Hyperfine, Inc.'s Q2 2026 earnings call
Gross margins remain above 50% for the fourth consecutive quarter, while the company reiterates its full-year revenue guidance of $20-22 million.
GUILFORD, Conn., August 06, 2026--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced second quarter 2026 financial results and provided a business update.
OrthoPediatrics (KIDS) delivered earnings and revenue surprises of +16.13% and +3.64%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
GUILFORD, Conn., July 30, 2026--Multiple peer-reviewed publications in Journal of Neurosurgery and Stroke strengthen evidence for portable MRI in stroke and neurosurgical settings.
GUILFORD, Conn., July 23, 2026--Hyperfine will report Q2 2026 financial results Thur., Aug. 6, 2026. Management will host a corresponding conference call at 1:30 PM PT/4:30 PM ET.
The introduction of Model 2 into Europe aims to support Hyperfine’s international commercial objectives.
GUILFORD, Conn., July 01, 2026--Hyperfine initiates the launch of the next-gen Swoop® system in Europe, beginning global expansion of its most advanced portable MRI technology.
GUILFORD, Conn., June 22, 2026--Leading neurosurgeons will help guide the role of the Swoop® system in neurosurgical care, including workflow, product capabilities, and evidence.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.